Zevra Therapeutics Inc ZVRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ZVRA is a good fit for your portfolio.
News
-
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
-
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
-
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Trading Information
- Previous Close Price
- $4.75
- Day Range
- $4.79–4.97
- 52-Week Range
- $3.89–7.28
- Bid/Ask
- $4.50 / $4.81
- Market Cap
- $201.30 Mil
- Volume/Avg
- 169,547 / 246,459
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.21
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 69
- Website
- https://www.zevra.com
Comparables
Valuation
|
Metric
|
ZVRA
|
CBAY
|
MORF
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.23 | 12.65 | 2.26 |
Price/Sales | 6.21 | 111.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ZVRA
CBAY
MORF
Financial Strength
|
Metric
|
ZVRA
|
CBAY
|
MORF
|
|---|---|---|---|
Quick Ratio | 1.15 | 10.70 | 28.43 |
Current Ratio | 1.18 | 10.96 | 28.94 |
Interest Coverage | −32.70 | −5.27 | — |
Quick Ratio
ZVRA
CBAY
MORF
Profitability
|
Metric
|
ZVRA
|
CBAY
|
MORF
|
|---|---|---|---|
Return on Assets (Normalized) | −31.82% | −30.06% | −18.85% |
Return on Equity (Normalized) | −59.02% | −51.97% | −19.43% |
Return on Invested Capital (Normalized) | −45.99% | −30.87% | −23.26% |
Return on Assets
ZVRA
CBAY
MORF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dcqjwnhcf | Ksjj | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hxlngzyx | Flxnrql | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vmzyrwbqn | Tfjrtyw | $103.7 Bil | |
MRNA
| Moderna Inc | Kfpvfcggj | Gtft | $47.9 Bil | |
ARGX
| argenx SE ADR | Qkxqbdhx | Zzxq | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Mhsppjbp | Cqt | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kfndrtpw | Shxlc | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wmrgbwcs | Mkffhp | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Whxxpgfml | Pdxlhwm | $12.8 Bil | |
INCY
| Incyte Corp | Nblrlrkf | Ppjnqc | $12.1 Bil |